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Introduction
A prominent role for the renin-angiotensin system
(RAS) in blood pressure and fluid homeostasis has
been long recognized (1, 2). However, angiotensin II,
the major biologically active peptide produced by the
RAS, also has nonhemodynamic actions that may
mediate end-organ injury in diseases such as hyperten-
sion and congestive heart failure (1, 2). For example,
angiotensin II stimulates growth and hypertrophy of
vascular smooth muscle cells and cardiac myocytes (3).
Accordingly, in addition to their hemodynamic bene-
fits, the effectiveness of pharmacologic antagonists of
the RAS in cardiovascular diseases has been attributed,
in part, to inhibition of these cellular actions of
angiotensin II (1, 2). Virtually all the classically recog-
nized actions of the RAS, including the nonhemody-
namic actions just listed, are mediated by angiotensin
II signaling through type 1 (AT1) receptors (1, 2).
Although humans have only a single AT1 receptor iso-
form, mice have 2 AT1 receptor isoforms, AT1A and
AT1B, that are encoded by distinct genes (Agtr1a and
Agtr1b) (4, 5). The murine AT1A receptor is the predom-
inantly expressed isoform in most tissues (6, 7) and is
the closest homologue to the human AT1 receptor.
In addition to its effects to promote cell growth and pro-
liferation, emerging evidence has suggested that the RAS
may also have potent proinflammatory effects that may
contribute to disease pathogenesis. For example, in cell-
culture and whole-animal experiments, angiotensin II, act-
ing through AT1 receptors, stimulates the production of
inflammatory mediators such as TNF-α, TGF-β, and
MCP-1 (8). In some cell types, stimulation of AT1 recep-
tors is coupled to activation of JAK/STAT kinase systems
(9–11). These signaling pathways are also used by T-cell
cytokines such as IL-2 and γ-IFN (12). Although previous
studies have suggested that the RAS may influence certain
immunological functions, their results are conflicting and
evidence for such actions is largely indirect (13–19). More-
over, a number of recent studies have demonstrated pro-
tective effect of RAS antagonists in immunologically
mediated diseases such as myocarditis and chronic allo-
graft rejection and in antiglomerular basement mem-
brane nephritis (20–25). However, the mechanism of the
beneficial actions of RAS inhibitors to prevent immuno-
logical injury in these models is not clear.
Various components of the RAS are expressed on
inflammatory cells, and AT1 receptors are present on T
cells and macrophages (26–28). To explore the effects
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of the RAS acting through AT1 receptors to regulate
immune responses, we used mice in which the gene
encoding the AT1A receptor (Agtr1a) had been disrupt-
ed by gene targeting (29). Our studies suggest that
angiotensin II functions as an autocrine factor in
alloimmune responses, promoting T-cell proliferation.
Methods
Animals. Mice lacking AT1A receptors for angiotensin II
were generated by homologous recombination in
embryonic stem cells as described previously (29). To
avoid the potential confounding effect of heteroge-
neous genetic background on the interpretation of our
experiments, the Agtr1a mutation was backcrossed for
more than 10 generations onto the C57BL/6 back-
ground. Agtr1a genotypes, designated (+) for the wild-
type allele, and (–) for the targeted allele, were deter-
mined by Southern blot analysis of DNA isolated from
tail biopsies as described elsewhere (29). Inbred
C57BL/6 Agtr1a+/+ or Agtr1a–/– mice were used in all the
experiments. Animals were bred and maintained in the
animal facility of the Durham VA Medical Center
under National Institutes of Health guidelines.
[125I]Angiotensin II receptor autoradiography. Angiotensin
II binding in whole spleen was determined by receptor
autoradiography as we have described previously (29).
Spleens were removed from Agtr1a+/+ and Agtr1a–/– mice,
and the tissues were embedded in OTC compound
(Miles Inc., Elkhart, Indiana, USA) and frozen in liquid
nitrogen-chilled isopentane. Tissue blocks were sec-
tioned serially (15 µm) on a cryostat and thaw-mounted
on glass microscope slides (FisherPlus; Fisher Scientific,
Pittsburgh, Pennsylvania, USA). The sections were incu-
bated with buffer containing 200 pM [125I]angiotensin
II. Excess concentrations (10 µM) of unlabeled
angiotensin II, losartan (AT1 receptor antagonist), or
PD123319 (AT2 receptor antagonist) were added to
some sections to define specificity of binding. After incu-
bation for 1 hour, the slides were washed, dried
overnight, and then exposed to high-resolution x-ray
film (Hyperfilm-betamax; Amersham International, Lit-
tle Chalfont, Buckinghamshire, United Kingdom).
Radioligand binding studies using [125I]angiotensin II.
Angiotensin II binding in splenocytes was assessed by
radioligand binding as described previously (30), using
[125I]angiotensin II. Splenocyte suspensions were pre-
pared from Agtr1a+/+ and Agtr1a–/– mice by gently grind-
ing the spleen between glass slides. The cells were washed
once in PBS and then resuspended in ice-cold PBS con-
taining 10 mM Tris HCl (pH 7.4), 1% BSA. Aliquots of 5
× 105 splenocytes were incubated in triplicate with 20
pM [125I]angiotensin II for 30 minutes at 37°C with or
without excess concentrations of unlabeled angiotensin
II, losartan, or PD123319. The incubation mixtures were
filtered through Whatman GF/C glass fiber filters (VWR
Scientific, Westchester, Pennsylvania, USA). After wash-
ing, cell-bound labeled counts were determined using a
gamma counter, and specific binding was calculated
using standard formulas (30).
Identification of AT1A receptor mRNA by RT-PCR. Expres-
sion of AT1A receptor mRNA was assessed by RT-PCR as
described previously (7). Splenocytes were prepared from
Agtr1a+/+ and Agtr1a–/– mice as already described here.
Splenic T cells were isolated using a commercial separa-
tion column (R&D Systems Inc., Minneapolis, Min-
nesota, USA), splenic B cells were isolated by panning
using a polyvalent anti-mouse IgG antibody, and splenic
macrophages were isolated by plastic adherence. Total
RNA was isolated from these cell preparations using Tri-
reagent (Sigma Chemical Co., St. Louis, Missouri, USA),
and 0.5 µg was reverse-transcribed using oligo-dT
primers. AT1A receptor cDNA was amplified in PCR reac-
tions using the following primers: sense 5′-GCAT-
CATCTTTGTGGTGGG-3′ and antisense 5′-ATCAGCA-
CATCCAGGAATG-3′. The PCR products were size
fractionated on 1.8% agarose in TBE gels, stained with
ethidium bromide, and photographed.
Cytofluorometric survey of lymphoid organs in Agtr1a+/+
and Agtr1a–/– mice. Flow cytometry on splenocytes and
thymocytes was performed as described previously (31).
Briefly, spleen and thymus were isolated from Agtr1a+/+
and Agtr1a–/– mice, and cell suspensions were obtained
by gently grinding the tissue between sterile glass slides.
Cells were counted and resuspended (2 × 106 cells/mL)
in cold FACS buffer (PBS/2% FBS/0.05% NaN3).
Aliquots of resuspended cells (100 µL) were incubated
with optimal concentrations of antibody for 30 min-
utes at 4°C and were washed 3 times in FACS buffer.
The antibodies used were as follows: RM2-5 (anti-
CD2), 145-2C11 (anti-CD3), GK 1.5 (anti-CD4), 53-6.7
(anti-CD8), 30-H122 (anti-Thy 1.2), H57-597 (anti-
αβTCR), PK136/DX5 (anti-NK1.1), RA36B2 (anti-
B220), and M1/70 (anti-CD11b) (all from PharMingen,
San Diego, California, USA). An irrelevant isotypic anti-
body R35-95 (rat IgG2a; PharMingen) was used as a
control for nonspecific staining. After final washing,
cells were fixed with PBS containing 2% formalin and
were analyzed within 72 hours. Analyses and sorting
were performed in a FACscan (Becton Dickinson,
Mountain View, California, USA). Forward scatter
threshold was set to exclude dead cells and debris from
acquisition. At least 1 × 104 cells were analyzed for each
antibody or antibody combination.
Effects of angiotensin II on proliferation of splenocytes. Sin-
gle-cell suspensions of splenocytes were prepared from
Agtr1a+/+ and Agtr1a–/– mice as already described here.
The cells were incubated in complete RPMI containing
1% FBS and rested in media containing 1 µM of the
ACE-inhibitor enalapril and 1 µM indomethacin at
37°C for 12 hours. A range of concentrations of
angiotensin II was added to the cells with or without the
AT1 receptor antagonist losartan or the calcineurin
phosphatase inhibitor cyclosporine. After 18 and 30
hours of culture, 0.5 µCi of [3H]thymidine was added to
each well, and the cells were incubated for an additional
12 hours at 37°C. Cell proliferation was assessed by the
amount of [3H]thymidine incorporated by cells. To cal-
culate specific [3H]thymidine incorporation, 3H counts
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per minute from wells without angiotensin II were sub-
tracted from the wells containing angiotensin II.
Mixed lymphocyte responses. Primary 1-way mixed lym-
phocyte responses (MLRs) were performed as described
previously (31). Single-cell suspensions of responder
splenocytes were reconstituted at various concentra-
tions and were mixed with irradiated stimulator
splenocytes at the indicated ratios. Fifty microliters of
each cell suspension were added to individual wells of
a 96-well plate with or without pharmacologic
inhibitors. After varying periods of incubation, cells
were pulsed with 0.5 µCi of [3H]thymidine per well for
the final 18 hours of culture. The cells were harvested,
and cell-associated [3H]thymidine content was deter-
mined by scintillation counting. Values are expressed
as specific counts per minute (counts from wells with
responders only were subtracted from counts from
wells with responders and stimulators), with each point
measured in triplicate or quadruplicate samples.
Mouse heart transplantation. Heterotopic cardiac trans-
plants in mice were performed as described previously
(31). The recipient C57BL/6 (H-2b) Agtr1a+/+ and
Agtr1a–/– mice were anesthetized with isoflurane and
prepared by separating the aorta and vena cava between
the renal vessels and the bifurcation of the iliacs. The
donor heart was harvested from an MHC-disparate
(DBA/2 × BALB/c)F1 (H-2d) mouse, and an end-to-side
anastomosis was created between the recipient aorta
and the ascending aorta from the donor heart. A simi-
lar anastomosis was then created between the recipient
vena cava and the superior vena cava of the donor
heart. The total ischemic time averaged 15 minutes and
was not different between the groups. Surgical mortal-
ity of the recipients was less than 5%. All transplant
recipients were treated with subtherapeutic doses (10
or 20 mg/kg by subcutaneous injection) of
cyclosporine beginning on the day of transplant and
continuing for 7 days. Allograft survival was monitored
by direct palpation of the heartbeat through the
abdominal wall, and graft failure was defined as the
cessation of palpable heartbeat.
To examine further the effect of the Agtr1a mutation
on the character of rejection, we evaluated the
histopathology of cardiac allografts in the experimen-
tal groups. In additional groups of Agtr1a+/+ (n = 7) and
Agtr1a–/– (n = 6) animals, cardiac transplants were per-
formed as already described here and the recipients
were treated with 20 mg/kg per day of cyclosporine by
subcutaneous injection. On day 5 after transplanta-
tion, the allografts were removed and placed in 10%
buffered formalin. After formalin fixation, the hearts
were sectioned, stained with hematoxylin and eosin,
and the slides were reviewed by a pathologist (P. Ruiz)
who was masked to the treatment groups. The severity
of rejection, interstitial infiltrates, myocyte injury, and
vascular abnormalities were each graded separately
using a semiquantitative scale where 0 was no abnor-
mality and 1, 2, and 3 represented mild, moderate, and
severe abnormalities, respectively.
Statistical analysis. The values for each parameter with-
in a group are expressed as the mean ± SEM. For com-
parisons between Agtr1a+/+ and Agtr1a–/– groups, statis-
tical significance was assessed using an unpaired t test
for normally distributed data. A paired t test was used
for comparisons within groups. For nonparametric
analyses, a Mann-Whitney U test was used.
Results
To determine whether the RAS might have direct effects
on the immune system, we first characterized angiotensin
receptors on lymphoid tissue by receptor autoradiogra-
phy (29). As shown in Figure 1a, binding of
[125I]angiotensin II was easily detected throughout the
parenchyma of the spleen. The vast majority of
[125I]angiotensin II binding was specific and was dis-
placed by the addition of excess concentrations of unla-
beled angiotensin II (data not shown). To differentiate
between the 2 classes of angiotensin II receptors (AT1 and
AT2), we determined the proportion of [125I]angiotensin
II binding that could be displaced by specific antagonists
for the receptor subtypes. In mouse spleen, most of the
[125I]angiotensin II binding was displaced by the AT1
receptor antagonist losartan (Figure 1b). The AT2 recep-
tor antagonist PD123319 had no effect on
[125I]angiotensin II binding in spleen (data not shown).
To characterize further angiotensin II binding sites in
splenic lymphocytes, we performed radioligand bind-
ing studies in single-cell suspensions prepared from
spleens of C57BL/6 Agtr1a+/+ and Agtr1a–/–mice (31).
Specific [125I]angiotensin II binding was readily detect-
ed in splenocytes from wild-type mice, and the major
portion of this binding was displaced by losartan (Fig-
ure 2). In contrast, total and losartan-displaceable
binding of [125I]angiotensin II to AT1A receptor-defi-
cient cells was not different from background. We used
an RT-PCR assay to determine which cell populations
within the spleen expressed AT1A receptor mRNA. As
depicted in Figure 3, AT1A receptor mRNA could be
amplified from RNA prepared from populations of T
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Figure 1
Angiotensin binding in mouse spleen. (a) Total [125I]angiotensin II
binding in a section of normal mouse spleen. (b) [125I]Angiotensin II
binding in the presence of excess concentrations of the AT1 receptor
antagonist losartan.
cells, B cells, or macrophages that were isolated from
spleens of wild-type C57BL/6 mice. Thus, the AT1A
receptor is, by far, the predominant angiotensin II
receptor expressed by immune cells in the spleen.
In other cell types such as vascular smooth muscle
cells, angiotensin II stimulates cell growth and prolif-
eration (3, 32, 33). To examine the function of
angiotensin receptors expressed by inflammatory cells,
we tested whether angiotensin II could induce prolif-
eration of splenic lymphocytes. After incubation with
1 µM concentrations of an angiotensin-converting
enzyme (ACE) inhibitor to block endogenous
angiotensin II synthesis, splenocytes from wild-type
and Agtr1a–/– mice were exposed to increasing concen-
trations of angiotensin II peptide. As shown in Figure
4, angiotensin II alone was sufficient to cause prolifer-
ation of splenic lymphocytes from Agtr1a+/+ animals.
The magnitude of the response was dose dependent,
and the maximal effect was observed at angiotensin II
concentrations of 1–3 µM. The actions of angiotensin
II to stimulate proliferation of wild-type cells were com-
pletely blocked by the AT1 receptor antagonist losartan
(data not shown). Moreover, as shown in Figure 4,
splenocytes from AT1A receptor–deficient mice do not
proliferate in response to angiotensin II, indicating that
these actions are mediated by AT1A receptors.
To examine whether angiotensin II receptors con-
tribute to proliferation during an ongoing immune
response, we measured alloantigen-induced prolifera-
tion of splenic lymphocytes isolated from C57BL/6 (H-
2b) Agtr1a+/+ and Agtr1a–/– mice in a 1-way MLR. After 5
days in culture with irradiated, allogeneic (H-2d) stimu-
lators, proliferative responses were approximately 50%
lower in AT1A receptor–deficient cells than controls
across a range of stimulator cell concentrations (Figure
5a). This was not simply a difference in the kinetics of
the response, as proliferation by AT1A receptor–deficient
cells was also reduced after 3, 4, and 5 days in MLRs
(Figure 5b). When purified T cells were used as respon-
ders, significantly less proliferation was once again
observed in the T cells lacking AT1A receptors compared
with controls (5,807 ± 1,437 vs. 2,568 ± 760; P = 0.0013).
In contrast, there was no difference in the level of pro-
liferation in reverse MLR using Agtr1a+/+ and Agtr1a–/–
cells as stimulators (data not shown). When anti-CD3
antibody was used as a stimulus, proliferation of AT1A
receptor–deficient cells was also significantly reduced
compared with controls (Figure 5c). However, prolifer-
ative responses after exposure to the nonspecific mito-
gen concanavalin A were not different between the
groups. Therefore, stimulation of the AT1A receptor
occurs as a part of normal cellular immune responses
promoting lymphocyte proliferation. The actions of
AT1A receptors to enhance splenocyte proliferation are
most prominent when activation is triggered through
stimulation of the T-cell receptor/CD3 complex.
To determine whether the Agtr1a mutation might
produce gross abnormalities in development of the
immune system, we examined the size and cellular con-
stitution of the major lymphoid organs in Agtr1a+/+ and
Agtr1a–/– mice. As depicted in Table 1, there were no dif-
ferences between the AT1A receptor–deficient mice and
controls. To confirm that the defect in proliferation
was due to reduced angiotensin II signaling and not to
a subtle developmental abnormality in the AT1A recep-
tor–deficient mice, 1-way MLR experiments were per-
formed in the presence of the ACE inhibitor enalapril
or the AT1 receptor antagonist losartan. Both agents
caused dose-dependent reductions in proliferative
responses when added to MLR cultures of Agtr1a+/+
cells (Figure 6). Moreover, the maximal inhibition
induced by the 2 pharmacologic RAS inhibitors was
approximately 50% of control values, similar to the
diminution seen in MLRs with Agtr1a–/– cells. The
actions of the ACE inhibitor to suppress proliferation
in the MLR were reversed by the simultaneous admin-
istration of 10 µM angiotensin II on day 0 of culture
(control MLR: 6,678 ± 276 cpm; enalapril alone: 2,884
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Figure 2
[125I]Angiotensin II radioligand binding in mouse splenocytes.
[125I]Angiotensin II radioligand binding in cell suspensions prepared
from whole spleen from Agtr1a+/+ (open bars) and Agtr1a–/– (filled
bars) mice. Total binding is shown in the left, and binding in the pres-
ence of the AT1 receptor antagonist losartan is shown on the right.
Table 1
Analysis of lymphoid organs 
Agtr1a+/+ Agtr1a–/–
Spleen
Total cell no. 1.15 × 108 1.17 × 108
αβTCR+ 29.1 ± 2.0% 26.5 ± 3.9%
CD4+ 19.1 ± 2.0% 18.7 ± 3.2%
CD8+ 10.4 ± 1.1% 11.0 ± 1.5%
Thy1.2+ 25.6 ± 1.6% 27.0 ± 2.4%
B220+ 49.1 ± 3.1% 49.9 ± 2.8%
F480+ 15.3 ± 2.1% 11.9 ± 3.5%
NK1.1+ 7.5 ± 1.0% 7.2 ± 0.7%
Thymus
Total cell no. 9.4 × 107 9.4 × 107
αβTCR+ 15.2 ± 0.2% 18.8 ± 4.3%
CD4+CD8+ 86.1 ± 1.2% 87.0 ± 1.0%
CD4+CD8- 4.9 ± 0.3% 4.4 ± 0.4%
CD4-CD8+ 4.1 ± 0.5% 4.3 ± 1.4%
Thy1.2+ 91.0 ± 5.3% 94.9 ± 4.5%
± 192 cpm; P < 0.0001 versus control; enalapril +
angiotensin II: 7,664 ± 427; P < 0.0001 versus enalapril
alone). Taken together, these data demonstrate that
angiotensin II acts as an autocrine growth factor to
augment T-cell proliferation in MLRs. They also sug-
gest that ample components of the RAS are present in
mixed lymphocyte culture to produce angiotensin II in
sufficient quantities to induce cellular effects.
Because of the important role of calcineurin phos-
phatase in T-cell activation in alloimmune responses
(34–36), along with recent studies demonstrating acti-
vation of calcineurin in cardiac myocytes by angiotensin
II (37–39), we considered the possibility that calcineurin
might play a role in the stimulation of lymphocyte pro-
liferation by AT1 receptors. To examine the role of the
pathway of calcineurin and a family of transcription fac-
tors named nuclear factor of activated T cells (NFATs)
in angiotensin II–induced lymphocyte growth, we incu-
bated splenic lymphocytes with 1 µM angiotensin II in
the presence of increasing concentrations of the cal-
cineurin inhibitor cyclosporine. Cyclosporine caused a
dose-proportional inhibition of angiotensin II–stimu-
lated lymphocyte proliferation (Figure 7), and at the
highest dose (3 ng/mL), the effect of angiotensin II to
promote splenocyte proliferation was completely
blocked. To determine whether these actions have any
relevance to an in vivo immune response, we used a het-
erotopic cardiac allograft model (31). C57BL/6 Agtr1a+/+
and Agtr1a–/– mice were transplanted with H-2 disparate
cardiac allografts and were treated with subtherapeutic
doses (10 or 20 mg/kg) of cyclosporine for 7 days. Allo-
graft survival was monitored by direct palpation of the
heartbeat through the abdominal wall. Without treat-
ment, survival of cardiac allografts in this aggressive
model of acute rejection was similar in Agtr1a+/+ and
Agtr1a–/–recipients (9 ± 1 and 10 ± 2 days, respectively).
As shown in Figure 8, administration of 10 or 20 mg/kg
per day of cyclosporine had little effect on allograft sur-
vival in the wild-type animals (10 ± 1 and 11 ± 1 days).
In contrast, graft survival was significantly prolonged
in the AT1A receptor–deficient animals (13 ± 1 days with
10 mg/kg and 16 ± 1 days with 20 mg/kg; P < 0.014 ver-
sus wild-type), demonstrating that simultaneous inhi-
bition of AT1 and calcineurin signaling have cooperative
effects to ameliorate allograft rejection.
To determine whether the absence of AT1A receptors
altered the character of intragraft inflammation, allo-
graft histopathology was examined on day 5 after trans-
plantation in additional groups of Agtr1a+/+ and
Agtr1a–/–mice that had been treated with 20 mg/kg per
day of cyclosporine. As shown in Table 2, the severity of
each abnormality tended to be less in the Agtr1a–/– recip-
ients than controls. In particular, the degree of myocyte
injury was reduced in the AT1A receptor–deficient recip-
ients (P = 0.05 versus wild-type). 
Discussion
Accumulating evidence over the past few years has sug-
gested that angiotensin II might be produced by and act
directly on immune cells. For example, Gomez and asso-
ciates reported that rat leukocytes express angiotensino-
gen mRNA and synthesize angiotensinogen protein
(28). Moreover, angiotensin peptides are released by rat
alveolar macrophages (39), mouse lymphocytes, and
granuloma cells in murine schistosomiasis (14, 40).
Addition of angiotensinogen or angiotensin I peptides
to immune cell preparations can augment the release of
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Figure 3
AT1A receptor mRNA expression in cell populations isolated from
spleen. AT1A receptor mRNA expression in spleen assessed by RT-
PCR. Total RNA was isolated, and RT-PCR was performed using
primers specific for the AT1A receptor (7). The PCR products were
size fractionated on an agarose gel that was stained with ethidium
bromide. The 457-bp PCR product is easily seen in samples from iso-
lated splenic T cells (lane 2), B cells (lane 3), and macrophages (lane
4), or unseparated splenocytes (lane 5) from a wild-type mouse. No
product was detected in RNA isolated from splenocytes of an AT1A
receptor–deficient mouse (lane 6).
Figure 4
Angiotensin II stimulates splenocyte proliferation. Concentrations of
angiotensin II in the range of 0.01–3 µM were added to single-cell
suspensions of splenocytes from wild-type (open bars) and Agtr1a–/–
mice (filled bars). Proliferation was assessed 48 hours later as
[3H]thymidine incorporation. *P < 0.001 versus 0 µM angiotensin II;
**P < 0.0001 versus 0 µM angiotensin II; ¶P < 0.03 versus Agtr1a+/+;
†P < 0.008 versus Agtr1a+/+; ‡P < 0.001 versus Agtr1a+/+.
angiotensin II (14), implying that these cells possess the
requisite enzymatic machinery to perform the complete
conversion of angiotensinogen substrate to active
angiotensin II. Although some studies suggest that
these pathways may be independent of renin and/or
ACE (41), ACE activity and mRNA expression have been
documented in macrophages and T cells (42–47), and
ACE expression may be upregulated in inflammatory
conditions (42, 43). Enhanced expression of ACE in
inflammatory cells has been linked to diseases such as
sarcoidosis (42, 43), although its pathophysiological
role has not been defined. Local accumulation of ACE
has also been identified in atherosclerotic lesions, par-
ticularly in regions of inflammatory cell infiltration
(48). In these settings, it has been suggested that local
expression and accumulation of ACE may contribute to
enhanced production of angiotensin II in tissues.
The potential for angiotensin II to directly modulate
inflammatory cell functions was suggested by the obser-
vation that human mononuclear leukocytes express spe-
cific binding sites for angiotensin II (27). Tsutsumi and
associates subsequently demonstrated large numbers of
binding sites for angiotensin II in rat spleen and found
that these sites were primarily AT1 receptors (26). This is
consistent with our receptor autoradiography findings
of diffuse AT1-specific binding in mouse spleen, depict-
ed in Figure 1a. Our studies further show that these are
predominantly AT1A receptors and that AT1A receptors
are expressed in a variety of splenocyte populations
including T cells, macrophages, and B cells.
Effects of angiotensin II to modulate T-cell functions
have also been suggested by previous studies. In a pre-
liminary report, Vance and Kelly reported that prolif-
eration of a nephritogenic T-cell clone was significant-
ly augmented by the addition of angiotensin II and that
this effect seemed to be mediated by AT1 receptors (49).
In contrast, Simon and associates reported inhibition
of PHA-induced proliferation by angiotensin II (50).
Thus, although the data are conflicting, there are sev-
eral reports suggesting that angiotensin II modulates
immune functions and that this peptide may have
direct effects on T-cell proliferation. In the experiments
described here, we find that exposure of splenocytes to
angiotensin II, with no other exogenous stimulus, is
sufficient to trigger proliferation. This response is
blocked by specific AT1 receptor antagonists and it is
absent in cells from Agtr1a–/– mice, indicating that these
effects are mediated by AT1A receptors.
To determine whether the actions of angiotensin II to
stimulate lymphocyte proliferation play a role in modu-
lating immune responses, we used the MLR as a model
of the cellular alloimmune response. The MLR is
designed to mimic the conditions that might occur in a
transplanted organ when recipient immune cells are acti-
vated by recognition of foreign MHC antigens expressed
on the donor tissue. When the responder cell population
came from Agtr1a–/– mice that lack AT1A receptors, we
found that proliferative responses in MLR were signifi-
cantly reduced, by approximately 50%. Proliferation was
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Figure 5
MLRs and responses to mitogens by splenocytes from Agtr1a+/+
and Agtr1a–/– mice. (a) MLR using splenocytes from C57BL/6 (H-
2b) Agtr1a+/+ and Agtr1a–/– mice as responders and irradiated
splenocytes from (BALB/c × DBA/2)F1 (H-2d) mice as stimula-
tors. [3H]Thymidine incorporation is significantly reduced in
splenocytes from Agtr1a–/– mice (filled bars) compared with
Agtr1a+/+ controls (open bars) across a wide range of stimulator
concentrations. *P < 0.001 versus Agtr1a–/–. (b) Proliferative
responses in MLR were measured after 3, 4, and 5 days in culture
comparing C57BL/6 wild-type (open bars) and Agtr1a–/– (filled
bars) responder cells. *P < 0.04 versus Agtr1a+/+; †P < 0.0001 ver-
sus Agtr1a+/+. (c) The effects of concanavalin A (left) and anti-
CD3 antibodies (right) on proliferation of splenocytes isolated
from Agtr1a+/+ (open bars) and Agtr1a–/– mice (filled bars). Pro-
liferation is once again measured as [3H]thymidine incorporation.
*P < 0.01 versus Agtr1a+/+; †P < 0.002 versus Agtr1a+/+.
also reduced when purified T cells from Agtr1a–/– mice
were used as responders. Because AT1 receptors are also
normally expressed on antigen-presenting cells, we test-
ed whether the response would be affected if AT1A recep-
tors were absent from stimulator cells that provide the
antigenic stimulus to trigger the MLR. In this case, pro-
liferation was similar to that induced by wild-type stim-
ulators. Taken together, these data suggest that reduced
proliferation of AT1A receptor–deficient cells in MLR is
due to the absence of direct effects of angiotensin II on
responder cell populations, including T cells.
We have extensively analyzed the lymphoid organs of
Agtr1a–/– mice by size, cell numbers, and cell constituents
and have found no discernible differences compared
with wild-type animals (see Table 1). Nonetheless, to
ensure that the differences in MLR were not due to a
subtle developmental defect caused by the absence of
AT1A receptors, we also performed MLR experiments in
wild-type cells in the presence of an ACE inhibitor or an
AT1 receptor antagonist. Both inhibition of angiotensin
II production and blockade of AT1 receptors produced a
dose-dependent inhibition of the proliferative response.
The level of inhibition achieved by pharmacologic block-
ade, approximately 50% of normal, was similar to that
seen in the genetic experiments. The similarity between
the effects of ACE inhibition and AT1 receptor blockade
suggests that virtually all the effects of angiotensin II to
modulate T-cell proliferation are mediated by AT1 recep-
tors. These experiments also suggest that adequate com-
ponents of the RAS are present in cultured splenocytes
to produce angiotensin II in sufficient quantities to
induce cellular effects. Therefore, these studies identify
a “tissue RAS” in lymphoid organs that contributes to
the regulation of cellular immune responses.
The differential effects of the Agtr1a mutation on pro-
liferation induced by anti-CD3 antibody compared with
the nonspecific mitogen concanavalin A suggest that the
actions of AT1A receptors to modulate T-cell proliferation
may be specific for stimulation through the TCR/CD3
complex. Engagement of the T-cell receptor with antigen
in the setting of appropriate costimulation causes a brisk
increase in intracellular calcium (51). This leads to acti-
vation of calcineurin, a calcium- and calmodulin-
dependent phosphatase (34) that dephosphorylates
NFATs  (34–36, 52–54). Once these proteins are dephos-
phorylated by calcineurin, they translocate to the nucle-
us where they directly activate transcription of genes that
promote T cell activation and proliferation (55). AT1
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Figure 6
The effects of RAS inhibitors on lymphocyte proliferation. A range of
concentrations of the ACE inhibitor enalapril or the AT1 receptor
antagonist losartan were added to a 1-way MLR. Proliferation was
measured as specific incorporation of [3H]thymidine. Both losartan
(open bars) and enalapril (filled bars) caused significant, dose-
dependent reductions in proliferation of wild-type splenocytes in
MLR. *P < 0.005 versus no drug.
Table 2
Histopathological scores for cardiac allografts on day 5 after transplantation
Groups Interstitial infiltrates Myocyte injury Acute rejection Perivascular infiltrates Venulitis Arteriolitis
Agtr1a+/+ 1.8 ± 0.2 1.4 ± 0.2 1.7 ± 0.1 1.4 ± 0.2 1.3 ± 0.2 0.8 ± 0.3
Agtr1a–/– 1.4 ± 0.4 0.7 ± 0.3A 1.3 ± 0.3 1.0 ± 0.2 1.2 ± 0.2 0.6 ± 0.3
AP = 0.05 versus Agtr1a+/+.
Figure 7
The effects of calcineurin inhibition on angiotensin II–stimulated lym-
phocyte proliferation. Splenocyte suspensions from C57BL/6 wild-
type mice were cultured with 1 µM angiotensin II along with 0.3 or 3
ng/mL cyclosporine, or its vehicle alone; after 24 hours [3H]thymidine
incorporation was determined. Baseline proliferation, in the absence
of angiotensin II, was similar between the groups: 2,094 ± 125 cpm
for vehicle; 1,791 ± 168 cpm for 0.3 ng/mL cyclosporine; and 1,789
± 245 cpm for 3 ng/mL cyclosporine. *P < 0.02 versus vehicle.
receptor stimulation is coupled to increased intracellu-
lar calcium levels in a number of systems (1) including
human PBMCs (56). Accordingly, we considered the pos-
sibility that stimulation of AT1 receptors on lymphocytes
leads to an increase in intracellular calcium concentra-
tion and that this AT1-mediated calcium signal triggers
calcineurin and NFAT activation. In support of this pos-
sibility, recent studies have demonstrated that AT1 recep-
tor stimulation is sufficient to activate the calcineurin-
NFAT pathway in cardiac myocytes and this activation
leads to alterations of cell phenotype that can be inhibit-
ed by cyclosporine. In the heart, this pathway seems to be
an important cause of myocardial hypertrophy (37, 38).
To examine the role of the calcineurin-NFAT pathway
in the angiotensin II–mediated lymphocyte proliferation,
we used cyclosporine, a specific inhibitor of calcineurin
phosphatase (52). Cyclosporine completely blocked the
ability of angiotensin II to induce proliferation of cul-
tured splenic lymphocytes, demonstrating that cal-
cineurin is required for stimulation of lymphocyte pro-
liferation by AT1 receptors. To determine whether this
pathway is operative during an immune response in an
intact animal, we studied the effects of the Agtr1a muta-
tion on cyclosporine responses in a mouse model of car-
diac transplant rejection. In this model, donor and recip-
ient are completely mismatched at the MHC locus,
resulting in a very aggressive acute cellular rejection
response to the allograft. Using these strain combina-
tions, doses of cyclosporine of approximately 100 mg/kg
per day are generally required to achieve prolongation of
graft survival. In wild-type animals, doses of cyclosporine
that were an order of magnitude below this therapeutic
level had no effect on graft survival. In contrast, these
small doses of cyclosporine caused a significant prolon-
gation of graft survival in mice lacking AT1A receptors on
their lymphocytes. This result demonstrates the rela-
tionship between AT1 receptor signaling and calcineurin
activation in an alloimmune response in vivo and sug-
gests that these pathways cooperate to promote allograft
injury in this model. Because AT1A receptor expression is
normal in the donor heart, these actions result from the
absence of AT1A receptor signaling in recipient tissues.
Although these transplant studies provide proof of the
concept that AT1 receptor signaling on immune cells con-
tributes to in vivo alloimmune responses, the effect in
this powerful model of acute rejection is relatively mod-
est. However, it is possible that the relative contribution
of this pathway may be more significant in more indolent
alloimmune responses, such as in chronic allograft rejec-
tion or in patients who are being treated with therapeu-
tic doses of immunosuppressive agents. In this regard, a
number of studies in animal models have demonstrated
an important role for the renin-angiotensin system in the
pathogenesis of chronic allograft rejection. For example,
several groups have demonstrated that AT1 receptor
blockade significantly ameliorates kidney injury in rat
models of chronic renal allograft rejection and that these
effects are not due to reduction in systemic blood pres-
sure (22–24). In a model of chronic rejection of cardiac
allografts, AT1 receptor blockade significantly amelio-
rates intimal proliferation of coronary arteries, the patho-
logical lesion that characterizes chronic rejection (20).
The efficacy of RAS antagonists in immunological dis-
eases has largely been attributed to effects on vasculature
and production of inflammatory mediators. Our studies
suggest that blockade of direct actions of angiotensin II
to promote the T-cell response may also contribute to
these beneficial effects.
In summary, these studies identify potent effects of the
RAS to modulate the immune system. Because inflam-
mation is critical to the pathogenesis of diseases such as
atherosclerosis (57), the effects of angiotensin II on
immune cell activation may contribute to the pathologi-
cal effects of RAS dysregulation in cardiovascular disease.
The enhanced sensitivity of AT1A receptor–deficient mice
to the immunosuppressive actions of cyclosporine sug-
gests a rationale for the use of RAS antagonists in
patients with organ transplants who are being treated
with calcineurin inhibitors. In this setting, antagonism
of the RAS may potentiate the immunosuppressive
effects of calcineurin inhibition reducing the doses
required to achieve adequate immunosuppression and
therefore limiting dose-related toxicity.
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